Association between circulating matrix metalloproteinase levels and coronary plaque regression after acute coronary syndrome - Subanalysis of the JAPAN-ACS study

Atherosclerosis

Volumn 226, Issue 1, 2013, Pages 275-280

  Ogita, Manabu ^a   Miyauchi, Katsumi ^a   Morimoto, Takeshi ^b   Daida, Hiroyuki ^a   Kimura, Takeshi ^c   Hiro, Takafumi ^d   Nakagawa, Yoshihisa ^e   Yamagishi, Masakazu ^f   Ozaki, Yukio ^g   Matsuzaki, Masunori ^h  

^a JUNTENDO UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d NIHON UNIVERSITY   (Japan)

^e TENRI HOSPITAL   (Japan)

^f KANAZAWA UNIVERSITY   (Japan)

^g FUJITA HEALTH UNIVERSITY   (Japan)

^h YAMAGUCHI UNIVERSITY   (Japan)

Author keywords

Acute coronary syndrome; Coronary plaque; Intravascular ultrasound; Matrix metalloproteinases; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; INTERSTITIAL COLLAGENASE; PITAVASTATIN; STROMELYSIN; SULFONYLUREA; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY PLAQUE; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ACUTE CORONARY SYNDROME; CORONARY ARTERY DISEASE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; PROSPECTIVE STUDIES; PYRROLES; QUINOLINES; REMISSION INDUCTION;

EID: 84871372560     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.10.063     Document Type: Article

References (30)

1. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators.
2. De Lemos J.A., Blaziong M.A., Wiviott S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004, 292:1307-1316.
3. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992, 326:242-250. 310-318.
4. Kaneda H., Ako J., Terashima M. Intravascular ultrasound imaging for assessing regression and progression in coronary artery disease. Am J Cardiol 2010, 106:1735-1746.
5. Hiro T., Kimura T., Morimoto T., et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multi-center randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS study). J Am Coll Cardiol 2009, 293:293-302. JAPAN-ACS Investigators.
6. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071-1080. REVERSAL Investigators.
7. Okazaki S., Yokoyama T., Miyauchi K., et al. Early statin treatment in patients with acute coronary syndrome; demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 2004, 110:1061-1068.
8. Dabek J., Kulach A., Gasior Z. The role of matrix metalloproteinases in acute coronary syndromes. Eur J Intern Med 2007, 18:463-466.
9. Jones C.B., Sane D.C., Herrington D.M. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003, 59:812-823.
10. Galis Z., Sukhova G., Lark M., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503.
11. Kai H., Ikeda H., Yasukawa H., et al. Peripheral blood levels of matrix metalloporteases-2, and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998, 32:368-372.
12. Inoue T., Kato T., Takayanagi K., et al. Circulating matrix metalloproteinase-1, and -3 in patients with an acute coronary syndrome. Am J Cardiol 2003, 92:1461-1464.
13. Miyauchi K., Kimura T., Morimoto T., et al. Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) rationale and design. Circ J 2006, 70:1624-1628.
14. Mintz G.S., Nissen S.E., Anderson W.D., et al. American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). J Am Coll Cardiol 2001, 37:1478-1492.
15. Hiro T., Kimura T., Morimoto T., et al. Diabetes Mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome. Circ J 2010, 74:1165-1174. JAPAN-ACS Investigators.
16. Galis Z.S., Khhatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002, 90:251-262.
17. Mostafa Mtairag E., Chollet-Martin S., Oudghiri M., et al. Effects of interleukin-10 on monocyte/endothelial cell adhesion and MMP-9/TIMP-1 secretion. Cardiovasc Res 2001, 49:882-890.
18. Dollery C.M., Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res 2006, 69:625-635.
19. Henney A.M., Wakeley P.R., Davies M.J., et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 1991, 88:8154-8158.
20. Schoenhagen P., Vince D.G., Ziada K.M., et al. Relation of matrix metalloproteinase-3 found in coronary lesion samples retrieved by directional coronary atherectomy to intravascular ultrasound observations on coronary remodeling. Am J Cardiol 2002, 89:1354-1359.
21. Johnson J.L., George S.J., Newby A.C., Jackson C.L. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA 2005, 102:15575-15580.
22. Nakaya R., Uzui H., Shimizu H., et al. Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction. Int J Cardiol 2005, 105:67-73.
23. Kelly D., Khan S., Cockerill G., et al. Circulationg Stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodeling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail 2008, 10:133-139.
24. Sukhova G., Williams J.K., Libby P. Stains reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 2002, 22:1452-1458.
25. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103:926-933.
26. Luan Z., chase A.J., Newby A.C. Statin inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003, 23:769-775.
27. Tziakas D.N., Chalikias G.K., Parissis J.T., et al. Serum profiles of matrix metalloproteases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int J Cardiol 2004, 94:269-277.
28. Gresele P., Falcinelli E., Loffredo F., et al. Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation. Eur Heart J 2011, 32:316-325.
29. Beyzade S., Zhang S., Wong Y., Ian N.M.D., Eriksson P., Ye S. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J Am Coll Cardiol 2003, 41:2130-2137.
30. Wang J., Xu D., Wu X., et al. Polymorphisms of matrix metalloproteinases in myocardial infarction: a meta-analysis. Heart 2011, 97:1542-1546.